Abstract
Updated Safety and Efficacy from the Copanlisib CHRONOS-1 Trial in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma: Low Incidence of Late-Onset Severe Toxicities
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have